Von Eschenbach May Speed Changes In “Strategic Direction” At FDA – Galson
Executive Summary
FDA Acting Commissioner Andrew von Eschenbach could serve as a catalyst for policy initiatives at the agency, Center for Drug Evaluation & Research Director Steve Galson said Oct. 24
You may also be interested in...
FDA’s Drug Center Reorganization Creates Second Safety Director Position
The Center for Drug Evaluation & Research will divide its drug safety functions between a new associate center director and its existing Office of Drug Safety